Option Care Health Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Option Care Health (OPCH)

Option Care Health’s credibility took a major hit after a sudden guidance cut and stock crash.

What the company is saying

Option Care Health’s core narrative, as presented in the recent disclosures, is that the company is committed to transparency and prudent financial management, even when that means revising expectations downward. Initially, management wanted investors to believe that the business was on track for steady growth, reaffirming FY 2026 net revenue guidance of $5.8 billion to $6 billion and projecting 4% growth at the midpoint. The specific language used—such as CFO Meenal Sethna’s statement that they 'feel very good about' the guidance and remain confident in achieving it—was designed to instill confidence and signal operational stability. The announcement on February 24, 2026, emphasized this confidence and continuity, with repeated reassurances about the achievability of targets. However, the subsequent April 30, 2026, communication buried the abruptness of the change, focusing instead on the technical reasons for the cut—'lower CID patient retention and therapy mix'—and quantifying the impact as an 'extra 200 basis points' above prior estimates. The tone shifted from confident to defensive, with management attempting to frame the reduction as a measured response to evolving conditions rather than a sign of deeper issues. Notably, CFO Meenal Sethna is the only named executive, and her role as the financial spokesperson is significant because it places direct accountability for the guidance and its revision on her office. This narrative fits a broader investor relations strategy of managing expectations tightly, but the rapid reversal within just 65 days undermines the credibility of prior communications. Compared to earlier messaging, the shift is stark: from repeated, confident reaffirmations to a sudden, material downgrade, with little warning or incremental disclosure in between.

What the data suggests

The disclosed numbers show a clear and abrupt deterioration in the company’s financial outlook. On February 24, 2026, Option Care Health set FY 2026 net revenue guidance at $5.8 billion to $6 billion, targeting 4% growth at the midpoint. Just 65 days later, this was slashed to $5.675 billion to $5.775 billion, representing up to a 3.75% reduction and only 1% growth at the midpoint versus the prior year. The company attributes this to lower CID patient retention and an unfavorable therapy mix, with an additional 200 basis points of negative impact above previous estimates. The immediate market reaction was severe: shares fell approximately 26.4% at the open and reached a 30% decline by midday on April 30, 2026. This suggests that the market was blindsided by the magnitude and speed of the guidance cut, and that prior guidance was viewed as credible until the reversal. There is a significant gap between management’s earlier claims of confidence and the reality evidenced by the numbers; the company failed to meet its own targets and provided little advance warning. The financial disclosures are clear regarding the guidance ranges and percentage changes, but lack depth—there is no actual Q1 2026 revenue, adjusted EBITDA, or operational detail, making it difficult to assess the full scope of the problem. An independent analyst, looking only at the numbers, would conclude that the company’s growth trajectory has stalled, management’s forecasting reliability is in question, and investor trust has been materially damaged.

Analysis

The announcement is factual and negative in tone, focusing on a sharp downward revision of revenue guidance and the resulting stock price decline. Most claims are realised and supported by specific numerical disclosures, such as the revised guidance range and the percentage drop in share price. Only a minority of statements are forward-looking, and these are limited to management's prior confidence in guidance, which has since been invalidated by the downward revision. There is no evidence of exaggerated or promotional language; the narrative is proportionate to the disclosed facts. No large capital outlay or long-dated, uncertain returns are mentioned. The gap between narrative and evidence is minimal, as the announcement centers on realised negative developments.

Risk flags

• ●Forecasting reliability risk: Management reaffirmed guidance with high confidence just 65 days before slashing it by up to 3.75%. This rapid reversal raises serious questions about the company’s ability to accurately forecast its own business, which is critical for investor trust and valuation.
• ●Operational risk: The guidance cut was attributed to lower CID patient retention and therapy mix, but the company did not provide detailed quantification or operational metrics. This lack of transparency makes it difficult to assess whether these are isolated issues or symptoms of broader operational challenges.
• ●Disclosure risk: The company’s financial disclosures are limited to revenue guidance ranges and percentage changes, with no actual Q1 2026 revenue, adjusted EBITDA, or other key metrics provided. This restricts investors’ ability to independently verify the severity or causes of the downturn.
• ●Market confidence risk: The share price fell 26.4% at open and 30% by midday following the announcement, indicating that the market was not prepared for such a negative revision and that investor confidence has been severely damaged.
• ●Pattern risk: The abruptness of the guidance cut, following repeated reassurances, suggests a pattern of overconfidence or poor internal controls around forecasting and disclosure. This increases the risk of further negative surprises.
• ●Legal risk: The announcement references a shareholder legal investigation into whether Option Care Health made materially false or misleading statements regarding its FY 2026 outlook. This introduces the possibility of litigation, regulatory scrutiny, and further reputational damage.
• ●Forward-looking risk: While most claims are now realised, the company’s prior forward-looking statements proved unreliable. Investors should be cautious about any future guidance until management demonstrates improved forecasting discipline.
• ●Execution risk: The company’s ability to stabilize patient retention and therapy mix is unproven, and without more granular disclosure, it is unclear how quickly or effectively these issues can be addressed.

Bottom line

For investors, this announcement signals a material deterioration in both the company’s financial outlook and management’s credibility. The sharp downward revision of FY 2026 revenue guidance—just 65 days after a confident reaffirmation—suggests that Option Care Health either failed to detect emerging problems or was slow to communicate them. The immediate 26.4% to 30% share price collapse reflects a loss of market trust and a repricing of risk. There are no notable institutional figures or outside investors mentioned whose involvement might offset these concerns. To change this assessment, the company would need to provide detailed operational metrics (such as actual Q1 2026 revenue, adjusted EBITDA, and patient retention data), a clear action plan for addressing the underlying issues, and evidence of improved forecasting discipline. In the next reporting period, investors should watch for: actual revenue and profitability figures, updated guidance, and any signs of stabilization or further deterioration in patient retention and therapy mix. Given the magnitude and speed of the guidance cut, this is not a signal to buy the dip; rather, it is a warning to monitor closely for further negative developments or evidence of a turnaround. The single most important takeaway is that Option Care Health’s management has lost credibility with the market, and until they rebuild trust through transparent, accurate disclosures and operational improvement, the stock will likely remain under pressure.

Announcement summary

Option Care Health (NASDAQ:OPCH) reiterated its net revenue guidance of $5.8 billion to $6 billion for FY 2026 on February 24, 2026, but reduced this range to $5.675 billion to $5.775 billion just 65 days later. The downward revision represented up to a 3.75% decrease from the previous guidance and was attributed to lower CID patient retention and therapy mix. Following the announcement of the revised guidance on April 30, 2026, OPCH shares fell approximately 26.4% at market open and reached a 30% decline by midday. Investors who suffered losses are encouraged to contact Levi & Korsinsky to discuss their legal rights.

Disagree with this article?